- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00787826
Continued Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine
April 28, 2021 updated by: U.S. Army Medical Research and Development Command
A Longitudinal Phase 2 Study for the Continued Evaluation of the Safety and Immunogenicity of a Live Francisella Tularensis Vaccine, NDBR 101, Lot 4 in Healthy Adults At-Risk for Exposure to Francisella Tularensis
This study is designed to determine the safety and immunogenicity of a Live Francisella tularensis Vaccine
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Detailed Description
Study Objectives:
- To assess the safety of live F. tularensis vaccine NDBR 101.
- To assess the immunogenicity of live F. tularensis vaccine NDBR 101.
Study Type
Interventional
Enrollment (Anticipated)
1000
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Fort Deterick, Maryland, United States, 21702
- U.S. Army Medical Research Institute of Infectious Diseases
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- At least 18 years old.
- Females of childbearing potential must agree to have a urine or serum pregnancy test on vaccination day, immediately before vaccination (Exception: documented hysterectomy or > 3 years of menopause). The results must be negative. Subjects must agree not to become pregnant for 3 months after receipt of the vaccine.
- Subjects must be at risk for exposure to F. tularensis.
- Subjects must have an up-to-date (within 1 year) medical history including concomitant medications, physical examination, and laboratory tests on their charts and be medically cleared for participation by an investigator.
- Subject must be willing to return for all follow-up visits on days 1 and 2, between days 5-9, 12-16, 28-35, and 56-84 (if needed), all visits for serology, and the closeout interview 6 months (±14 days) after vaccination or revaccination.
- Subject must agree to report any adverse event which may or may not be associated with administration of the test article for at least 28 days after vaccination.
Exclusion Criteria:
- Over the age of 65 Years.
- Vaccinated against tularemia within the last 10 years or had a documented, confirmed tularemia infection.
- Clinically significant abnormal lab results including evidence of hepatitis C, hepatitis B carrier state, or elevated liver function tests (two times the normal range or at the discretion of the PI).
- Personal history of an immunodeficiency or current treatment with an oral or intravenous immunosuppressive medication.
- Confirmed HIV* infection.
- A medical condition that, in the judgment of the Principal Investigator (PI), would impact subject safety.
- Antibiotic therapy within 7 days before vaccination.
- Pregnancy or lactation. Subjects must agree not to become pregnant for 3 months after receipt of the vaccine.
Any known allergies to any component of the vaccine:
Modified casein partial hydrolysate medium Glucose cysteine hemin agar Sucrose gelatin agar stabilizer
- Administration of another vaccine within 4 weeks of tularemia vaccination.
- Any unresolved AE resulting from a previous immunization.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vaccination
Live Francisella Tularensis Vaccine
|
Approximately 0.0025 mL of vaccine will be administered percutaneously with a bifurcated needle using 15 pricks on the volar surface of the forearm.
Vaccination may be repeated up to two times within the year if successful vaccination is not demonstrated by a positive "take" reaction and a MA titer of ≥ 1:20.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number for adverse events.
Time Frame: 5 years
|
The nature (body system affected, type (local or systemic), severity, frequency of occurrence, relationship to vaccine, treatment or intervention offered if any, and resolution or outcome) and frequency of adverse events for the assessment population (all subjects receiving one or more vaccinations under this protocol).
|
5 years
|
Number of erythematous papule, vesicle, and/or eschar with or without underlying induration
Time Frame: 7 (± 2 days) after vaccination
|
Incidence of positive "take" reaction (development of an erythematous papule, vesicle, and/or eschar with or without underlying induration) following vaccination for all subjects regardless of compliance.
|
7 (± 2 days) after vaccination
|
Microagglutination (MA) titer that shows a ≥ 4-fold rise in antibody titer after vaccination.
Time Frame: 28-35 days
|
Seroconversion will be evaluated for subjects who are compliant with the titer schedule. Seroconversion is defined as microagglutination (MA) titer that shows a ≥ 4-fold rise in antibody titer after vaccination. |
28-35 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of tularemia cases following exposure to F. tularensis in a successfully vaccinated individual
Time Frame: 5 years
|
Documented occurrence of tularemia following exposure to F. tularensis in a successfully vaccinated individual (positive "take" reaction and seroconversion [≥ 4-fold rise in antibody titer after vaccination]).
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Anthony Cardile, DO, USAMRIID Medical Division
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 28, 2009
Primary Completion (Actual)
November 1, 2019
Study Completion (Anticipated)
December 1, 2021
Study Registration Dates
First Submitted
November 5, 2008
First Submitted That Met QC Criteria
November 6, 2008
First Posted (Estimate)
November 10, 2008
Study Record Updates
Last Update Posted (Actual)
April 29, 2021
Last Update Submitted That Met QC Criteria
April 28, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- A-15207.a
- FY 07-15 (Other Identifier: SIP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tularemia
-
National Institute of Allergy and Infectious Diseases...Completed
-
U.S. Army Medical Research and Development CommandUS Army Medical Research Institute of Infectious DiseasesWithdrawn
-
U.S. Army Medical Research and Development CommandCompleted
-
University Hospital, Basel, SwitzerlandKantonsspital St. Gallen, St. Gallen, SwitzerlandRecruitingLeptospirosis | Tularemia | Hepatitis E Virus InfectionSwitzerland
Clinical Trials on Live Francisella Tularensis Vaccine
-
National Institute of Allergy and Infectious Diseases...Completed
-
U.S. Army Medical Research and Development CommandCompleted
-
Changchun Keygen Biological Products Co., Ltd.Guangdong Provincial Institute of Biological Products And Materia MedicaCompletedJapanese Encephalitis | ChickenpoxChina
-
Cancer Institute and Hospital, Chinese Academy...Guangdong Center for Disease Prevention and ControlUnknown
-
Institute of Medical Biology, Chinese Academy of...Guangxi Center for Disease Control and PreventionCompleted
-
University of RochesterNational Institutes of Health (NIH)Withdrawn2009 H1N1 InfluenzaUnited States
-
Changchun BCHT Biotechnology Co.He Bei province Center for Disease control and preventionNot yet recruitingInfluenza PreventionChina
-
Vakzine Projekt Management GmbHUniversity of Stellenbosch; Farmovs-Parexel Bloemfontein, Republic of South... and other collaboratorsCompleted
-
Biofabri, S.LCentre Hospitalier Universitaire Vaudois; TuBerculosis Vaccine Initiative; Universidad...CompletedHealthy | TuberculosisSwitzerland
-
Changchun BCHT Biotechnology Co.He Bei province Center for Disease control and preventionRecruitingInfluenza PreventionChina